Has Coleen Schmidley received payments from drug or device companies?

Yes. Drug and device makers reported $6,618 in general payments to Coleen Schmidley across 360 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Coleen Schmidley did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Coleen Schmidley come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Coleen Schmidley

Nurse Practitioner · West Reading, PANPI 1194808774

Payments from drug & device makers

$6,618in general payments, 2019–2025

Across 360 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$902
Abbott$585
Boehringer Ingelheim$559
Novo Nordisk$490
AstraZeneca$465
Sanofi-aventis U.S. LLC$456
plus $3K from 22 others

What the payments were for

Food & beverage$6,606100%
Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	57	$902
Abbott	35	$585
Boehringer Ingelheim	27	$559
Novo Nordisk	30	$490
AstraZeneca	19	$465
Sanofi-aventis U.S. LLC	27	$456
Insulet Corporation	11	$353
Mannkind Corporation	14	$322
AbbVie	15	$318
Dexcom, Inc.	7	$274
Medtronic	8	$251
Amarin Pharma, Inc.	29	$250
Merck	14	$247
Corcept Therapeutics	10	$197
Bayer	10	$183
Amgen	13	$171
Tandem Diabetes Care, Inc.	9	$128
Cequr Corporation	5	$99
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$55
BD	2	$51
Novartis	2	$46
Zealand Pharma US, Inc.	2	$43
Xeris Pharmaceuticals, Inc.	2	$38
Ascensia Diabetes Care US Inc.	2	$37
Kowa Pharmaceuticals America, Inc.	3	$35
Esperion Therapeutics, Inc.	2	$26
Averitas Pharma Inc.	1	$23
Embecta Corp.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,618 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$56,878

Medicare patients

170

Services billed

739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	209	$259,066
Trijardy XrEmpaglifloz/Linaglip/Metformin	228	$247,906
OzempicSemaglutide	168	$199,197
JardianceEmpagliflozin	146	$158,383
FarxigaDapagliflozin Propanediol	156	$124,579
GlyxambiEmpagliflozin/Linagliptin	74	$95,088
RybelsusSemaglutide	62	$92,636
Synjardy XrEmpagliflozin/Metformin Hcl	102	$87,752
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	73	$82,800
Tresiba Flextouch U-200Insulin Degludec	62	$73,689
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	44	$70,461
Fiasp FlextouchInsulin Aspart (Niacinamide)	55	$58,512
TradjentaLinagliptin	42	$49,449
Soliqua 100-33Insulin Glargine/Lixisenatide	27	$39,072
TrulicityDulaglutide	31	$37,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimTrijardy Xr, Jardiance, Glyxambi, Synjardy Xr, Tradjenta	$559	$648,025610 claims
Novo NordiskOzempic, Rybelsus, Novolog	$490	$308,818295 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog	$902	$303,409257 claims
AstraZenecaFarxiga	$465	$124,579156 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus	$456	$40,07842 claims
MerckJanumet Xr	$247	$13,21912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.